Amylyx Pharmaceuticals securities fraud class action complaint survives motion to dismiss.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is being investigated for securities fraud class action complaint allegations, which have survived a motion to dismiss. Shareholders who purchased AMLX prior to May 11, 2023, and still hold shares today can seek corporate reforms, the return of funds, and a court-approved incentive award at no cost. Visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar, or call 267-507-6085 for more information.